It prevented the cells from getting there in the first place.
For patients whose melanoma has crossed into the brain, medicine has long offered little more than borrowed time — survival averaging a year, and the drugs that once worked falling silent. Researchers at the University of Utah's Huntsman Cancer Institute have identified a molecular driver of that deadly migration, an enzyme called FAK, and developed a two-drug oral combination that in preclinical models both treats existing brain tumors and prevents the cancer from arriving there at all. The work, now entering human clinical trials, carries particular weight for the rural Mountain West, where a pill taken at home may matter as much as the science behind it.
- Melanoma brain metastasis kills with grim efficiency — once the cancer reaches the brain, even the best available therapies lose their effectiveness and survival collapses to roughly one year.
- The discovery that an enzyme called FAK actively drives melanoma's spread to the brain gave researchers a precise target where previously there was none.
- A combination of two drugs — defactinib and avutometinib — blocked FAK and a secondary cancer-growth pathway simultaneously, producing striking results in mouse models: existing brain tumors treated, new metastases prevented, survival meaningfully extended.
- Because both drugs are taken orally, the therapy could reach patients in rural and frontier communities who cannot easily access hospital infusion centers — turning a scientific advance into a logistical one as well.
- Human trials are now enrolling at Huntsman Cancer Institute and the University of Iowa, where the coming months will test whether laboratory promise becomes clinical reality for patients who currently have no good options.
Melanoma that reaches the brain has long represented a clinical dead end. Survival averages about a year, and the drugs that controlled the cancer elsewhere in the body — immunotherapy, targeted oral therapies — lose their effectiveness once the disease crosses that threshold. For oncologists and their patients, it has been a diagnosis with few answers.
Sheri Holmen, a researcher at Huntsman Cancer Institute and professor of surgery at the University of Utah, spent years investigating why melanoma behaves so differently in the brain. Her team identified a key driver: an enzyme called focal adhesion kinase, or FAK, which regulates cell growth and appears to steer melanoma's spread toward the brain. That finding raised a pointed question — could blocking FAK stop the cancer from getting there at all?
Published in Cell Reports Medicine, the answer from preclinical models is a cautious yes. Holmen's team tested a combination of defactinib, which inhibits FAK, and avutometinib, which blocks the RAF and MEK proteins governing another cancer-growth pathway. In mouse models carrying a BRAF mutation — present in roughly half of all metastatic melanoma patients — the pairing both treated tumors already in the brain and prevented new metastases from forming. Survival rates improved significantly.
The therapy's form matters as much as its function. Both drugs are pills, taken at home. In a region like the Mountain West, where many patients live hours from specialized cancer centers and immunotherapy requires hospital infusions, an oral treatment could quietly transform who gets access to care.
The research, supported by the National Cancer Institute and developed with Verastem Oncology, has now moved into human trials at Huntsman Cancer Institute and the University of Iowa's Holden Comprehensive Cancer Center. Enrollment is open. What those trials reveal will determine whether this laboratory finding becomes a genuine lifeline — not just for patients near major medical centers, but for those who have always been hardest to reach.
Melanoma that reaches the brain is a death sentence dressed up in medical language. Once the cancer crosses that threshold, survival stretches to about a year on average, even with the best treatments available. The disease becomes resistant to the drugs that worked elsewhere in the body. Immunotherapy, the standard first line of attack for advanced melanoma, loses its punch. Targeted oral medications that patients take at home stop working as well. For oncologists and their patients, brain metastasis represents a clinical dead end—until now.
Sheri Holmen, a researcher at Huntsman Cancer Institute and professor of surgery at the University of Utah, has spent years asking why melanoma cells behave so differently once they settle in the brain. Her team identified a culprit: an enzyme called focal adhesion kinase, or FAK, which regulates cell growth and acts as a major driver of melanoma's spread to the brain. That discovery opened a door. If you could block FAK, could you stop the cancer from getting there in the first place?
The answer, according to research published in Cell Reports Medicine, appears to be yes—at least in preclinical models. Holmen's team tested a two-drug combination: defactinib, which inhibits FAK, paired with avutometinib, which blocks proteins called RAF and MEK that control another pathway of cancer cell growth. In mouse models of melanoma with a BRAF mutation—a genetic alteration found in roughly half of all metastatic melanoma patients—the combination did something remarkable. It not only treated tumors that had already spread to the brain; it prevented the cancer from getting there in the first place. Survival rates improved significantly.
The implications matter beyond the laboratory. Melanoma rates remain stubbornly high across the Mountain West, the region Huntsman serves. Many patients live in rural and frontier areas where access to specialized care means long drives or relocations. Immunotherapy requires hospital infusions. The new combination therapy comes as pills—oral drugs that patients can take at home, potentially transforming treatment for people who cannot easily travel to cancer centers.
Holmen frames this plainly: "Once melanoma has spread to the brain, it's very hard to treat. Metastasis to the brain is one of the main causes of death from melanoma." The window for intervention narrows dramatically once the disease reaches the brain. She and her colleagues wanted to address what she calls an unmet clinical need—patients with no other options. This research, supported by the National Cancer Institute and developed in partnership with Verastem Oncology, represents what she describes as a huge step forward.
The work has now moved into human trials. Huntsman Cancer Institute and Holden Comprehensive Cancer Center at the University of Iowa are enrolling patients with melanoma and brain metastases. The study remains open to eligible candidates. What happens in these clinical trials over the coming months and years will determine whether a laboratory finding translates into lives extended, suffering reduced, and treatment made accessible to people living far from major medical centers. For now, the research offers something melanoma patients with brain metastasis have lacked: a genuine alternative to the inevitable.
Notable Quotes
Once melanoma has spread to the brain, it's very hard to treat. Metastasis to the brain is one of the main causes of death from melanoma.— Sheri Holmen, PhD, Huntsman Cancer Institute
Not only did it treat the tumor once it spread to and was growing in the brain, it also prevented the cells from getting there in the first place.— Sheri Holmen, PhD, on the combination therapy
The Hearth Conversation Another angle on the story
Why does melanoma behave so differently once it reaches the brain? What makes that organ special?
The brain is protected by the blood-brain barrier—a selective filter that keeps many drugs out. Cancer cells that make it across that barrier also seem to activate different survival mechanisms. FAK appears to be one of those mechanisms, something the cancer relies on specifically in the brain environment.
So blocking FAK alone wasn't enough?
In the preclinical work, the combination of blocking FAK plus blocking RAF and MEK pathways worked better together than either alone. It's about hitting multiple switches at once.
The source mentions BRAF mutations in about half of metastatic melanoma patients. What about the other half?
That's the next frontier. This research focused on BRAF-mutant melanoma because it's common and well-understood. But the team will likely need to test whether the approach works in other melanoma subtypes, or whether different combinations are needed.
Why does immunotherapy stop working once cancer reaches the brain?
The brain's immune environment is different. It's more isolated, more protected. Immune cells have a harder time getting there and staying active. Once melanoma establishes itself in that sanctuary, the patient's own immune system becomes less effective.
For rural patients, what changes if this becomes standard treatment?
Everything. Instead of traveling to a hospital every few weeks for infusions, they take pills at home. That means fewer missed doses, fewer days away from family and work, and treatment that's actually sustainable for people living hours from the nearest cancer center.
What's the timeline for knowing if this actually works in people?
Clinical trials are just beginning. These things move slowly—months to years before we know if preclinical promise translates to real survival gains. But the fact that it's in trials now means the early signals were strong enough to justify testing it.